Activation of human liver 3alpha-hydroxysteroid dehydrogenase by clofibrate derivatives.
The NADP+-dependent dehydrogenase activity of a predominant isoenzyme of human liver 3alpha-hydroxysteroid dehydrogenase was activated by antihyperlipidemic drugs, such as bezafibrate and clinofibrate, and by clofibric acid and fenofibric acid (active metabolites of clofibrate and fenofibrate, respectively). The optimal pH of the activation by the drugs was about 7.5, and the concentrations giving maximum stimulation (1.8- to 2.4-fold) were 100, 50, 400 and 50 microM for bezafibrate, clinofibrate, clofibric acid and fenofibric acid, respectively. Clofibrate and fenofibrate acted as weak inhibitors, and the clofibric acid derivatives that lack the chloro group, methyl group on the alpha-carbon or carboxyl group greatly decreased the stimulatory effects. The activation by the drugs increased both Km and kcat (turnover number) values for the coenzyme and substrates. Kinetic analysis with respect to NADP+ showed that bezafibrate, clinofibrate, clofibric acid and fenofibric acid were nonessential activators showing dissociation constants of 32, 6, 103 and 11 microM, respectively. The combined activators experiments with one of the above drugs and sulfobromophthalein, a known activator specific for this enzyme, and comparison of their effects on the activities of mutant enzymes (with Met replacing Lys-270 or Arg-276) indicated that sulfobromophthalein and the drugs bind to an identical site on the enzyme. These results suggest that the long-term therapy with the antihyperlipidemic drugs influences the metabolism of steroid hormones, bile acids and several ketone-containing drugs mediated by the enzyme.
Matsuura
K
K
Laboratory of Biochemistry, Mitahora-higashi, Gifu, 502-8585 Japan, and Department of Pharmacy, Gifu University Hospital, Tsukasa-machi, Gifu, 500-8705 Japan.
Hara
A
A
Kato
M
M
Deyashiki
Y
Y
Miyabe
Y
Y
Ishikura
S
S
Sugiyama
T
T
Katagiri
Y
Y
D000429:Alcohol Oxidoreductases / Q000187:drug effects / Q000378:metabolism; D000449:Aldehyde Reductase; D000074408:Aldo-Keto Reductases; D001665:Binding Sites; D002994:Clofibrate / Q000031:analogs & derivatives / Q000494:pharmacology; D002995:Clofibric Acid / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D011345:Fenofibrate / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006913:Hydroxysteroid Dehydrogenases / Q000187:drug effects* / Q000302:isolation & purification / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000201:enzymology*
D000960:Hypolipidemic Agents; D002995:Clofibric Acid; D000429:Alcohol Oxidoreductases; D006913:Hydroxysteroid Dehydrogenases; D000074408:Aldo-Keto Reductases; D000449:Aldehyde Reductase; D002994:Clofibrate; D011345:Fenofibrate